Projects / Programmes source: ARIS

Vpliv antitrombotičnih postopkov na funkcijo žilnih pristopov za hemodializo (Slovene)

Research activity

Code Science Field Subfield
3.06.00  Medical sciences  Cardiovascular system   

Code Science Field
B007  Biomedical sciences  Medicine (human and vertebrates) 
B560  Biomedical sciences  Urology, nephrology 
vascular access, hemodialysis, antihrombotic regimen, function
Evaluation (rules)
source: COBISS
Researchers (11)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  01972  PhD Andrej Bren  Cardiovascular system  Researcher  2000 - 2001 
2.  10649  PhD Jadranka Buturović-Ponikvar  Cardiovascular system  Researcher  2000 - 2001 
3.  20956  Liljana Gaber    Researcher  1999 - 2001 
4.  01977  PhD Aljoša Kandus  Cardiovascular system  Researcher  2000 - 2001 
5.  09794  PhD Rajko Kenda  Human reproduction  Researcher  1999 - 2001 
6.  01982  PhD Radoslav Kveder  Cardiovascular system  Researcher  1999 - 2001 
7.  06203  PhD Marko Malovrh  Cardiovascular system  Researcher  1999 - 2001 
8.  01987  PhD Rafael Ponikvar  Cardiovascular system  Head  1999 - 2001 
9.  16238  MSc Vladimir Premru  Cardiovascular system  Researcher  1999 - 2001 
10.  10579  PhD Alenka Urbančič  Cardiovascular system  Researcher  2000 - 2001 
11.  08767  Janez Varl  Cardiovascular system  Researcher  1999 - 2001 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0312  University Medical Centre Ljubljana  Ljubljana  5057272000  125 
Vascular eccess is crucial factor for hemodialysis treatment. Native arteriovenous fistula, grafts and large bore vein chateters are the most important vascular access for hemodialysis. The most important reason for malfunction or failure of vascular access is thrombosis. Incidence of thrombosis could be reduced by using antihrobotic procedures and drugs. In the prospective clinical study which will be carried out in Dialysis Center, Department of Nephrology, University Medical Center Ljubljana, hemodialysis patients will be randomly divided in two groups after construction of arteriovenous fistula or graft. Group A will be consisted of patients which will be given antiaggregating drug ticlopidine and group B will be patients without antithrombotic medication after arteriovenous fistula or graft construction. The running time and function of AV fistula or graft will be assesed. We would like to check the hypothesis that antiaggregating drug ticlpidine improves patency and prolongs functioning time of AV fistula or graft. Patients who will need central venous catheters (either as temporary or permanent vascular access) will be divided into two groups according to anticoagulant solution with which the catheter will be locked during the interdialytic period. In group A will be patients whose catheter will be locked by heparin and in group B patients having catheters locked with citrate. The hypothesis is that citrate is as effective as heparin as concerns anticoagulant effect and is more suitable concerning side effects as systemic anticoagilation.
Views history